Los puntos clave no están disponibles para este artículo en este momento.
The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.
Pautier et al. (Wed,) studied this question.